RxDoctor Payments DataLook up a doctor →

David Zlotnick, MD

Interventional Cardiology · Buffalo, NYNPI 1366548364

Payments from drug & device makers

$816,515in general payments, 2019–2025

Across 931 payments — averaging $877.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$325K
  • Angiodynamics, Inc.$209K
  • Penumbra, Inc.$70K
  • Stryker$47K
  • EKOS Corporation$45K
  • Abiomed$31K
  • plus $89K from 24 others
$181in research payments, 2019–2025

Across 3 payments — averaging $60.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$181

What the payments were for

  • Consulting fees$211,59157%
  • Speaking & faculty fees$79,23521%
  • Grants$420%
  • Travel & lodging$60,56816%
  • Food & beverage$17,5865%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$816,515 in reported general payments places this provider in the 90th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$82,128
Medicare patients
222
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cilostazol15$393
Rosuvastatin Calcium28$311
Metoprolol Succinate12$276
Lisinopril21$269
Amlodipine Besylate20$196
Atorvastatin Calcium11$134

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →